Compare TG Therapeutics Inc (TGTX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Health Care Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 5.3× TG Therapeutics Inc's market cap, and Health Care Select Sector SPDR Fund is more actively traded (11,121,431 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| TGTX | XLV | |
|---|---|---|
Market Cap | $8.16B | $43.48B |
Volume | 1,735,121 | 11,121,431 |
Sector | Health | — |
52-Week High | $59.06 | $175.68 |
52-Week Low | $26.94 | $141.95 |
Typical Hold Time | 16 Days | 100 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
XLV trades at $168.16, down 0.39% with a bearish technical signal from moving averages. The healthcare ETF maintains strong cost advantages with a 0.08% expense ratio compared to peers. Recent news highlights XLV's defensive positioning during market volatility and its historical outperformance during Fed rate hikes. Technical indicators show RSI levels in neutral territory while ADX signals selling pressure.
XLV offers diversified healthcare exposure with competitive expense ratios, positioning it well for defensive investing. Key risks include political uncertainty around healthcare policy and concentrated exposure to domestic S&P 500 stocks. The ETF's low-cost structure and sector diversification provide stability amid market volatility, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
